FY2025 EPS Estimates for Vaxcyte Lowered by Leerink Partnrs

Vaxcyte, Inc. (NASDAQ:PCVX) – Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for Vaxcyte in a research report issued to clients and investors on Tuesday, November 18th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($6.44) per share for the year, down from their previous estimate of ($6.36). The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q4 2025 earnings at ($1.66) EPS, FY2026 earnings at ($7.40) EPS, FY2027 earnings at ($8.70) EPS, FY2028 earnings at ($9.42) EPS and FY2029 earnings at ($5.45) EPS.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter in the prior year, the company earned ($0.83) earnings per share.

Several other equities research analysts have also recently weighed in on PCVX. Cowen reiterated a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. Leerink Partners set a $77.00 price target on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 price target for the company. Finally, BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.83.

Vaxcyte Stock Performance

PCVX stock opened at $47.67 on Friday. The stock has a fifty day moving average of $40.76 and a 200-day moving average of $35.80. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $94.76. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of -9.85 and a beta of 1.07.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. Vanguard Group Inc. boosted its holdings in Vaxcyte by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock valued at $443,783,000 after acquiring an additional 323,368 shares during the period. RA Capital Management L.P. lifted its position in Vaxcyte by 40.3% in the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company’s stock valued at $460,262,000 after purchasing an additional 3,499,959 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Vaxcyte by 44.4% during the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock valued at $242,303,000 after purchasing an additional 1,972,918 shares during the period. State Street Corp grew its holdings in shares of Vaxcyte by 12.1% in the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock worth $160,672,000 after purchasing an additional 534,552 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP grew its holdings in shares of Vaxcyte by 12.2% in the third quarter. Paradigm Biocapital Advisors LP now owns 3,784,755 shares of the company’s stock worth $136,327,000 after purchasing an additional 411,918 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.